Comparative trial of the safety and immunogenicity of quadrivalent (A, C, Y, W-135) meningococcal polysaccharide-diphtheria conjugate vaccine versus quadrivalent polysaccharide vaccine in two- to ten-year-old children

Pediatric Infectious Disease Journal

Volumn 24, Issue 1, 2005, Pages 57-62

  Pichichero, Michael ^a   Casey, Janet ^b   Blatter, Mark ^c   Rothstein, Edward ^d   Ryall, Robert ^e   Bybel, Mike ^e   Gilmet, Gregory ^e   Papa, Thomas ^e  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b Elmwood Pediatric Group   (United States)

^c Pittsburgh Pediatric Research   (United States)

^d Pennridge Pediatric Associates   (United States)

^e SANOFI PASTEUR   (France)

Author keywords

Diphtheria; Immunogenicity; Meningococcal disease; Pediatrics; Vaccine

Indexed keywords

BACTERIAL VACCINE; MCV 4; MENINGOCOCCUS VACCINE; QUADRIVALENT MENINGOCOCCAL DIPHTHERIA CONJUGATE VACCINE; UNCLASSIFIED DRUG; BACTERIAL POLYSACCHARIDE; BACTERIUM ANTIBODY; DIPHTHERIA TOXOID; VACCINE;

ANOREXIA; ANTIBODY RESPONSE; ARTICLE; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIPHTHERIA; DOUBLE BLIND PROCEDURE; DROWSINESS; DRUG EFFICACY; DRUG SAFETY; EDEMA; ERYTHEMA; FEMALE; FEVER; HUMAN; IMMUNOGENICITY; INJECTION PAIN; INJECTION SITE REACTION; MAJOR CLINICAL STUDY; MALE; MENINGOCOCCOSIS; MULTICENTER STUDY; NEISSERIA MENINGITIDIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEROCONVERSION; SERUM BACTERICIDAL ACTIVITY; SKIN INDURATION; URTICARIA; VACCINATION; VIRUS STRAIN; VOMITING; BLOOD; CLASSIFICATION; COMPARATIVE STUDY; IMMUNOLOGY; PRESCHOOL CHILD; SEROTYPING;

ANTIBODIES, BACTERIAL; CHILD; CHILD, PRESCHOOL; DIPHTHERIA TOXOID; DOUBLE-BLIND METHOD; HUMANS; MENINGOCOCCAL INFECTIONS; MENINGOCOCCAL VACCINES; NEISSERIA MENINGITIDIS; POLYSACCHARIDES, BACTERIAL; SEROTYPING; VACCINES, CONJUGATE;

EID: 13944272312     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.inf.0000148928.10057.86     Document Type: Article

References (17)

1. Rosenstein NE, Perkins BA, Stephens DS, et al. Changing epidemiology of meningococcal disease in the United States, 1992-1996. J Infect Dis. 1999;180:1894-1901.
2. Schuchat A, Robinson K, Wenger JD, et al. Bacterial meningitis in the United States in 1995. N Engl J Med. 1997;337:970-976.
3. Centers for Disease Control and Prevention. Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR. 2000;49(RR-7):1-10.
4. Harrison LH, Pass MA, Mendelsohn AB, et al. Invasive meningococcal disease in adolescents and young adults. JAMA. 2001;286:694-699.
5. National Advisory Committee on Immunization. Supplementary statement on conjugate meningococcal vaccines. Can Commun Dis Rep. 2003;29:10-11.
6. Miller E, Salisbury D, Ramsay M. Planning, registration, and implementation of an immunization campaign against meningococcal serogroups C disease in the UK: a success story. Vaccine. 2001;20(suppl 1):S58-S67.
7. Ramsay ME, Andrews N, Kaczmarksi EB, et al. Efficacy of meningococcal serogroup C conjugate vaccine in teenagers and toddles in England. Lancet. 2001;357:195-196.
8. Centers for Disease Control and Prevention. Active Bacterial Core Surveillance (ABCs) Report, Emerging Infections Program Network, Neisseria meningitidis 2000. ABCs/NETSS; 2002.
9. Campbell JD, Edelman R, King JC, et al. Safety, reactogenicity, and immunogenicity of a tetravalent meningococcal polysaccharide-diphtheria conjugate vaccine given to healthy adults. J Infect Dis. 2002;186: 1848-1851.
10. Rennels M, King J Jr, Ryall R, Papa T, Froeschle J. Dosage escalation, safety, and immunogenicity study of four dosages of a tetravalent meninogococcal polysaccharide diphtheria toxoid conjugate vaccine in infants. Pediatr Infect Dis J. 2004;23:429-435.
11. Jodar L, Cartwright K, Feavers IM. Standardization and validation of serological assays for the evaluation of immune responses to Neisseria meningitidis serogroup A and C vaccines: meeting report. Biologicals. 2000;28:193-197.
12. Granoff D, Feavers, I, Borrow R. Meningococcal Vaccines: Plotkin-Ornstein Vaccines. 4th ed. Philadelphia, PA: W. B. Saunders; 2004.
13. Reingold AL, Broome CV, Hightower AW, et al. Age-specific differences in duration of clinical protection after vaccination with meningococcal polysaccharide A vaccine. Lancet. 1985;2:114-118.
14. Artenstein MS, Gold R, Zimmerly JG, et al. Prevention of meningococcal disease by group C polysaccharide vaccine. N Engl J Med. 1970; 282:417-420.
15. Gold R, Lepow ML, Goldschneider I, Draper TF, Gotshlich EC. Kinetics of antibody production to group A and group C meningococcal polysaccharide vaccines administered during the first six years of life: prospects for routine immunization of infants and children. J Infect Dis. 1979;140:690-697.
16. Rosenstein NE, Perkins BA, Stephens DS, et al. Meningococcal disease. N Engl J Med. 2001;344:1378-1388.
17. Pichichero ME, Casey JR, Papa T, Ryall R, Bybel M. A comparative trial of the safety and immunogenicity of quadrivalent (A, C, Y, W-135) meningococcal diphtheria conjugate vaccine (MCV-4) versus quadrivalent polysaccharide vaccine (Menomune, PS) in children 2-10 years of age. In: 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, September 14-17, 2003, Chicago. Washington, DC: American Society for Microbiology; 2003:286.